Asabys PartnersAsabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
ADVERTISEMENT
Asabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.